8-K Announcements
6Material company update
Apr 30, 2026·SEC
Material company update
Mar 5, 2026·SEC
Material company update
Feb 2, 2026·SEC
Lexicon Pharmaceuticals, Inc.(LXRX)Earnings, Financials & Key Ratios
LXRX•NASDAQ
$1.60
$678M mkt cap·Price updated May 6, 2026
AboutLexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.Show more
- Revenue$50M+60.2%
- EBITDA-$48M+75.4%
- Net Income-$50M+74.9%
- EPS (Diluted)-0.14+77.8%
- Gross Margin99.45%+1.5%
- EBITDA Margin-96.96%+84.7%
- Operating Margin-98.21%+84.5%
- Net Margin-101.08%+84.3%
- ROE-39.72%+76.3%
- ROIC-22.7%+72.0%
- Debt/Equity0.58-22.1%
- Interest Coverage-5.87+50.6%
LXRX Key Insights
Lexicon Pharmaceuticals, Inc. (LXRX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 15.7%
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 13.4% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
LXRX Price & Volume
Lexicon Pharmaceuticals, Inc. (LXRX) stock price & volume — 10-year historical chart
Loading chart...
LXRX Growth Metrics
Lexicon Pharmaceuticals, Inc. (LXRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-9.15%
5 Years15.72%
3 Years610.25%
TTM60.24%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM74.88%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM78.3%
Return on Capital
10 Years-42.34%
5 Years-67.7%
3 Years-67.98%
Last Year-23.44%
LXRX Recent Earnings
Lexicon Pharmaceuticals, Inc. (LXRX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 4/12 qtrs (33%)
Q2 2026Latest
Mar 5, 2026EPS
$0.04
Est $0.07
+42.9%
Revenue
$5M
Est $3M
+74.8%
Q4 2025
Nov 6, 2025EPS
$0.04
Est $0.07
+42.9%
Revenue
$14M
Est $3M
+351.4%
Q3 2025
Aug 6, 2025EPS
$0.01
Est $0.08
+112.5%
Revenue
$29M
Est $6M
+396.7%
Q2 2025
May 13, 2025EPS
$0.07
Est $0.10
+30.0%
Revenue
$1M
Est $1M
-3.4%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 5, 2026 | $0.04vs $0.07+42.9% | $5Mvs $3M+74.8% |
| Q4 2025 | Nov 6, 2025 | $0.04vs $0.07+42.9% | $14Mvs $3M+351.4% |
| Q3 2025 | Aug 6, 2025 | $0.01vs $0.08+112.5% | $29Mvs $6M+396.7% |
| Q2 2025 | May 13, 2025 | $0.07vs $0.10+30.0% | $1Mvs $1M-3.4% |
Based on last 12 quarters of dataView full earnings history →
LXRX Peer Comparison
Lexicon Pharmaceuticals, Inc. (LXRX) competitors in Metabolic and Obesity Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ARDX | 1.74B | 7.10 | -27.31 | 22.09% | -13.58% | -38.11% | 1.27 | |
 CORT | 5.6B | 52.15 | 63.60 | 12.79% | 6.23% | 7.5% | 0.01 | |
 INVA | 1.91B | 22.52 | 6.82 | 18.52% | 118.91% | 46.47% | 0.23 | |
 PTGX | 6.63B | 103.97 | -50.72 | -89.41% | -6.48% | -17.76% | 0.02 | |
 ACAD | 3.68B | 21.48 | 9.38 | 11.87% | 36.49% | 41.9% | 0.04 | |
 AGIO | 1.6B | 26.98 | -3.79 | 48.03% | -6.4% | -34.11% | 0.05 | |
 FOLD | 4.47B | 14.49 | -80.50 | 32.29% | -2.35% | -6.1% | 2.29 | |
 RARE | 2.55B | 25.93 | -4.45 | 20.13% | -91.03% | -6.08% |
Compare LXRX vs Peers
Lexicon Pharmaceuticals, Inc. (LXRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
LXRX Income Statement
Lexicon Pharmaceuticals, Inc. (LXRX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 90.33M | 63.21M | 322.07M | 24M | 298K | 139K | 1.2M | 31.08M | 49.8M |
| Revenue Growth % | 8.4% | -30.03% | 409.54% | -92.55% | -98.76% | -53.36% | 766.19% | 2481.48% | 60.24% |
| Cost of Goods Sold | 1.9M | 2.49M | 3.23M | 1.93M | 55.05M | 52.52M | 58.97M | 616K | 274K |
| COGS % of Revenue | 2.1% | 3.94% | 1% | 8.04% | 18471.81% | 37781.29% | 4898.01% | 1.98% | 0.55% |
| Gross Profit | 88.44M▲ 0% | 60.72M▼ 31.3% | 318.84M▲ 425.1% | 22.07M▼ 93.1% | -54.75M▼ 348.1% | -52.38M▲ 4.3% | -57.77M▼ 10.3% | 30.46M▲ 152.7% | 49.53M▲ 62.6% |
| Gross Margin % | 97.9% | 96.06% | 99% | 91.96% | -18371.81% | -37681.29% | -4798.01% | 98.02% | 99.45% |
| Gross Profit Growth % | 209.67% | -31.34% | 425.12% | -93.08% | -348.11% | 4.33% | -10.29% | 152.74% | 62.58% |
| Operating Expenses | 223.02M | 164M | 177.4M | 69.87M | 32.34M | 48.38M | 113.98M | 227.58M | 98.44M |
| OpEx % of Revenue | 246.88% | 259.45% | 55.08% | 291.17% | 10853.02% | 34807.91% | 9466.94% | 732.22% | 197.66% |
| Selling, General & Admin | 66.2M | 63.75M | 56.84M | 47.23M | 0 | 0 | 0 | 131.9M | 37.32M |
| SG&A % of Revenue | 73.29% | 100.86% | 17.65% | 196.83% | - | - | - | 424.38% | 74.93% |
| Research & Development | 156.81M | 100.24M | 91.92M | 153.62M | 55.05M | 52.82M | 58.89M | 84.48M | 61.12M |
| R&D % of Revenue | 173.59% | 158.59% | 28.54% | 640.22% | 18471.81% | 37997.12% | 4890.95% | 271.81% | 122.73% |
| Other Operating Expenses | 1.95M | 0 | 28.64M | -130.99M | -22.7M | -4.43M | 55.09M | 11.2M | 0 |
| Operating Income | -136.68M▲ 0% | -103.28M▲ 24.4% | 141.44M▲ 237.0% | -47.8M▼ 133.8% | -87.09M▼ 82.2% | -100.76M▼ 15.7% | -171.75M▼ 70.5% | -197.12M▼ 14.8% | -48.91M▲ 75.2% |
| Operating Margin % | -151.3% | -163.39% | 43.92% | -199.21% | -29224.83% | -72489.21% | -14264.95% | -634.2% | -98.21% |
| Operating Income Growth % | 0.35% | 24.44% | 236.95% | -133.79% | -82.2% | -15.7% | -70.45% | -14.77% | 75.19% |
| EBITDA | -133.28M | -99.6M | 145.1M | -44.87M | -86.8M | -100.33M | -171.2M | -196.58M | -48.29M |
| EBITDA Margin % | -147.54% | -157.57% | 45.05% | -186.98% | -29126.85% | -72182.01% | -14218.94% | -632.49% | -96.96% |
| EBITDA Growth % | 1.34% | 25.27% | 245.69% | -130.92% | -93.46% | -15.59% | -70.63% | -14.83% | 75.44% |
| D&A (Non-Cash Add-back) | 3.4M | 3.68M | 3.65M | 2.93M | 292K | 427K | 554K | 534K | 621K |
| EBIT | -128.67M | -99.77M | 144.79M | -44.03M | -87.09M | -100.46M | -170.31M | -184.82M | -48.91M |
| Net Interest Income | -5.03M | -17.27M | -17.33M | -11.78M | -668K | -1.18M | -5.37M | -3.29M | -1.43M |
| Interest Income | 1.95M | 3.51M | 3.35M | 2.77M | 134K | 1.6M | 7.73M | 12.29M | 6.91M |
| Interest Expense | 6.98M | 20.78M | 20.68M | 14.54M | 802K | 2.78M | 13.1M | 15.58M | 8.34M |
| Other Income/Expense | -5.03M | -17.27M | -17.33M | -10.77M | -668K | -1.18M | -5.37M | -3.29M | -1.43M |
| Pretax Income | -141.71M▲ 0% | -120.55M▲ 14.9% | 124.12M▲ 203.0% | -58.57M▼ 147.2% | -87.76M▼ 49.8% | -101.94M▼ 16.2% | -177.12M▼ 73.7% | -200.4M▼ 13.1% | -50.34M▲ 74.9% |
| Pretax Margin % | -156.87% | -190.71% | 38.54% | -244.11% | -29448.99% | -73341.01% | -14710.88% | -644.78% | -101.08% |
| Income Tax | -12.66M | 0 | -6.01M | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 8.93% | 0% | -4.85% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -129.05M▲ 0% | -120.55M▲ 6.6% | 130.13M▲ 208.0% | -58.57M▼ 145.0% | -87.76M▼ 49.8% | -101.94M▼ 16.2% | -177.12M▼ 73.7% | -200.4M▼ 13.1% | -50.34M▲ 74.9% |
| Net Margin % | -142.86% | -190.71% | 40.4% | -244.11% | -29448.99% | -73341.01% | -14710.88% | -644.78% | -101.08% |
| Net Income Growth % | 8.75% | 6.59% | 207.95% | -145.01% | -49.82% | -16.16% | -73.74% | -13.15% | 74.88% |
| Net Income (Continuing) | -122.99M | -120.55M | 130.13M | -58.57M | -87.76M | -101.94M | -177.12M | -200.4M | -50.34M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.23▲ 0% | -1.14▲ 7.3% | 1.11▲ 197.4% | -0.63▼ 156.8% | -0.61▲ 3.2% | -0.62▼ 1.6% | -0.80▼ 29.0% | -0.63▲ 21.3% | -0.14▲ 77.8% |
| EPS Growth % | 9.56% | 7.32% | 197.37% | -156.76% | 3.17% | -1.64% | -29.03% | 21.25% | 77.78% |
| EPS (Basic) | -1.23 | -1.14 | 1.23 | -0.63 | -0.61 | -0.62 | -0.80 | -0.63 | -0.14 |
| Diluted Shares Outstanding | 105.24M | 105.83M | 116.75M | 110.84M | 145.65M | 165.73M | 221.13M | 320.03M | 363.05M |
| Basic Shares Outstanding | 105.12M | 105.74M | 106.22M | 110.84M | 145.65M | 165.73M | 221.13M | 320.03M | 363.05M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
LXRX Balance Sheet
Lexicon Pharmaceuticals, Inc. (LXRX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 322M | 173.32M | 337.75M | 157.72M | 88.92M | 140.87M | 176.55M | 246.19M | 101.89M |
| Cash & Short-Term Investments | 310.79M | 160.05M | 271.66M | 152.28M | 86.74M | 138.36M | 170.03M | 237.96M | 96.23M |
| Cash Only | 310.79M | 160.05M | 36.11M | 126.26M | 64.06M | 46.34M | 22.46M | 66.66M | 34.33M |
| Short-Term Investments | 0 | 0 | 235.55M | 26.01M | 22.68M | 92.01M | 147.56M | 171.3M | 61.9M |
| Accounts Receivable | 4.83M | 5.92M | 56.53M | 395K | 14K | 28K | 1.01M | 3.47M | 2.38M |
| Days Sales Outstanding | 19.5 | 34.21 | 64.07 | 6.01 | 17.15 | 73.53 | 306.19 | 40.79 | 17.47 |
| Inventory | 1.95M | 4.68M | 4.24M | 0 | 0 | 0 | 381K | 231K | 281K |
| Days Inventory Outstanding | 374.42 | 685.75 | 479.32 | - | - | - | 2.36 | 136.88 | 374.32 |
| Other Current Assets | 4.43M | 2.67M | 0 | 0 | 0 | 2.48M | 5.13M | 4.53M | 3M |
| Total Non-Current Assets | 114.54M | 110.81M | 79.96M | 46.07M | 47.99M | 53.43M | 52.88M | 52.23M | 83.09M |
| Property, Plant & Equipment | 17.69M | 15.87M | 14.05M | 295K | 3.44M | 8.48M | 7.51M | 7.32M | 9.18M |
| Fixed Asset Turnover | 5.11x | 3.98x | 22.93x | 81.34x | 0.09x | 0.02x | 0.16x | 4.25x | 5.42x |
| Goodwill | 44.54M | 44.54M | 44.54M | 44.54M | 44.54M | 44.54M | 44.54M | 44.54M | 44.54M |
| Intangible Assets | 51.88M | 50.12M | 19.72M | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | -4.88M | -4.51M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 429K | 285K | 1.66M | 1.23M | 0 | 412K | 828K | 368K | 29.37M |
| Total Assets | 436.54M▲ 0% | 284.14M▼ 34.9% | 417.71M▲ 47.0% | 203.79M▼ 51.2% | 136.91M▼ 32.8% | 194.3M▲ 41.9% | 229.43M▲ 18.1% | 298.42M▲ 30.1% | 184.99M▼ 38.0% |
| Asset Turnover | 0.21x | 0.22x | 0.77x | 0.12x | 0.00x | 0.00x | 0.01x | 0.10x | 0.27x |
| Asset Growth % | -8.22% | -34.91% | 47.01% | -51.21% | -32.82% | 41.92% | 18.08% | 30.07% | -38.01% |
| Total Current Liabilities | 124.13M | 36.75M | 65.34M | 46.81M | 22.12M | 23.17M | 31.55M | 45.25M | 20.87M |
| Accounts Payable | 38.76M | 12.05M | 12.18M | 5.47M | 9.15M | 10.39M | 14.39M | 14.8M | 3.08M |
| Days Payables Outstanding | 7.45K | 1.77K | 1.38K | 1.03K | 60.69 | 72.25 | 89.06 | 8.77K | 4.11K |
| Short-Term Debt | 14.09M | 1.11M | 11.01M | 11.65M | 0 | 0 | 0 | 0 | 6.24M |
| Deferred Revenue (Current) | 40.1M | 3.4M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 252K | -1.06M | 9.64M | 6.2M | 5.71M | 3.66M | 9.59M | 14.71M | 11.55M |
| Current Ratio | 2.59x | 4.72x | 5.17x | 3.37x | 4.02x | 6.08x | 5.60x | 5.44x | 4.88x |
| Quick Ratio | 2.58x | 4.59x | 5.10x | 3.37x | 4.02x | 6.08x | 5.58x | 5.44x | 4.87x |
| Cash Conversion Cycle | -7.06K | -1.05K | -832.34 | - | - | - | 219.49 | -8.59K | -3.72K |
| Total Non-Current Liabilities | 260.31M | 273.79M | 235.27M | 611K | 1.19M | 54M | 104.77M | 107.22M | 56.58M |
| Long-Term Debt | 231.58M | 243.89M | 234.17M | 0 | 0 | 48.58M | 99.51M | 100.3M | 49.41M |
| Capital Lease Obligations | 0 | 0 | 1.1M | 611K | 1.19M | 5.42M | 5.26M | 6.92M | 6.59M |
| Deferred Tax Liabilities | 6.01M | 6.01M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 292K | 238K | 0 | 0 | 0 | 0 | 0 | 0 | 582K |
| Total Liabilities | 384.44M | 310.54M | 300.61M | 47.42M | 23.31M | 77.17M | 136.32M | 152.47M | 77.45M |
| Total Debt | 245.67M | 245M | 246.84M | 12.81M | 2.28M | 55.29M | 106.06M | 108.4M | 62.24M |
| Net Debt | -65.12M | 84.95M | 210.73M | -113.45M | -61.79M | 8.95M | 83.6M | 41.74M | 27.91M |
| Debt / Equity | 4.72x | - | 2.11x | 0.08x | 0.02x | 0.47x | 1.14x | 0.74x | 0.58x |
| Debt / EBITDA | - | - | 1.70x | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | 1.45x | - | - | - | - | - | - |
| Interest Coverage | -18.42x | -4.80x | 7.00x | -3.03x | -108.59x | -36.14x | -13.00x | -11.86x | -5.87x |
| Total Equity | 52.1M▲ 0% | -1.47B▼ 2924.4% | 117.1M▲ 108.0% | 156.37M▲ 33.5% | 113.59M▼ 27.4% | 117.12M▲ 3.1% | 93.11M▼ 20.5% | 145.95M▲ 56.8% | 107.54M▼ 26.3% |
| Equity Growth % | -66.9% | -2924.42% | 107.96% | 33.54% | -27.36% | 3.11% | -20.5% | 56.75% | -26.32% |
| Book Value per Share | 0.50 | -13.91 | 1.00 | 1.41 | 0.78 | 0.71 | 0.42 | 0.46 | 0.30 |
| Total Shareholders' Equity | 52.1M | -1.47B | 117.1M | 156.37M | 113.59M | 117.12M | 93.11M | 145.95M | 107.54M |
| Common Stock | 106K | 106K | 106K | 142K | 150K | 189K | 245K | 363K | 366K |
| Retained Earnings | -1.38B | -1.47B | -1.34B | -1.4B | -1.49B | -1.59B | -1.77B | -1.97B | -2.02B |
| Treasury Stock | -1.9M | -2.88M | -3.82M | -4.84M | -7.52M | -2.06M | -2.88M | -4.62M | -5.19M |
| Accumulated OCI | -222K | -12K | 84K | -6K | -10K | -428K | 31K | 119K | 30K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LXRX Cash Flow Statement
Lexicon Pharmaceuticals, Inc. (LXRX) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -185.39M | -148.61M | 113.81M | -142.97M | -87.02M | -88.85M | -161.9M | -178.78M | -67.85M |
| Operating CF Margin % | -205.23% | -235.1% | 35.34% | -595.83% | -29200.34% | -63921.58% | -13446.59% | -575.21% | -136.24% |
| Operating CF Growth % | -5.56% | 19.84% | 176.58% | -225.62% | 39.14% | -2.11% | -82.21% | -10.43% | 62.05% |
| Net Income | -129.05M | -120.55M | 130.13M | -58.57M | -87.76M | -101.94M | -177.12M | -200.4M | -50.34M |
| Depreciation & Amortization | 3.4M | 3.68M | 3.65M | 2.93M | 292K | 427K | 554K | 534K | 621K |
| Stock-Based Compensation | 9.47M | 11.7M | 14.22M | 13.27M | 10.58M | 11.52M | 14.34M | 13.5M | 12.52M |
| Deferred Taxes | -12.66M | 0 | -6.01M | -110K | 49K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 2.7M | 1.34M | 30.1M | -131.57M | 54K | 744K | -2.33M | -6.65M | -3.75M |
| Working Capital Changes | -59.26M | -44.77M | -58.29M | 31.08M | -10.23M | 402K | 2.66M | 14.24M | -26.89M |
| Change in Receivables | 166K | -1.1M | -50.61M | 53.23M | 381K | -14K | -982K | -2.46M | 1.09M |
| Change in Inventory | -1.95M | -2.73M | 437K | 345K | 0 | 0 | -381K | 150K | -50K |
| Change in Payables | -7.17M | -18.86M | 20.1M | -20.97M | -14.16M | 76K | 6.45M | 14.8M | -30.22M |
| Cash from Investing | 50.52M | 169.58M | -155.85M | 380.76M | 2.11M | -71.08M | -49.94M | -15.38M | 113.02M |
| Capital Expenditures | -228K | -95K | -70K | -87K | -1.22M | -1.33M | -470K | -1.03M | 0 |
| CapEx % of Revenue | 0.25% | 0.15% | 0.02% | 0.36% | 409.73% | 953.96% | 39.04% | 3.32% | - |
| Acquisitions | 0 | 0 | 155.78M | 11.01M | -3.33M | 69.75M | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 50.75M | 169.67M | -155.78M | 160.38M | 3.33M | -69.75M | 0 | 9.3M | 3.71M |
| Cash from Financing | 149.93M | -2.24M | -2.23M | -147.64M | 22.71M | 142.21M | 187.96M | 238.35M | -48.5M |
| Debt Issued (Net) | 143.63M | -2M | -1.28M | -216.58M | -11.7M | 48.87M | 49.96M | 0 | -48M |
| Equity Issued (Net) | 6.31M | -240K | -941K | -1.03M | 34.41M | -864K | 138M | 239.59M | 73K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -1.68M | -972K | -941K | -1.03M | -2.67M | -864K | -824K | -1.73M | 0 |
| Other Financing | 0 | 0 | 0 | 69.97M | 0 | 94.2M | 0 | -1.24M | -572K |
| Net Change in Cash | 15.06M▲ 0% | 18.73M▲ 24.3% | -44.27M▼ 336.4% | 90.15M▲ 303.6% | -62.2M▼ 169.0% | -17.72M▲ 71.5% | -23.88M▼ 34.8% | 44.19M▲ 285.1% | -3.33M▼ 107.5% |
| Free Cash Flow | -185.62M▲ 0% | -148.7M▲ 19.9% | 113.74M▲ 176.5% | -143.06M▼ 225.8% | -88.24M▲ 38.3% | -90.18M▼ 2.2% | -162.37M▼ 80.1% | -179.81M▼ 10.7% | -67.85M▲ 62.3% |
| FCF Margin % | -205.48% | -235.25% | 35.31% | -596.19% | -29610.07% | -64875.54% | -13485.63% | -578.52% | -136.24% |
| FCF Growth % | -5.55% | 19.89% | 176.49% | -225.78% | 38.32% | -2.2% | -80.05% | -10.74% | 62.27% |
| FCF per Share | -1.76 | -1.41 | 0.97 | -1.29 | -0.61 | -0.54 | -0.73 | -0.56 | -0.19 |
| FCF Conversion (FCF/Net Income) | 1.44x | 1.23x | 0.87x | 2.44x | 0.99x | 0.87x | 0.91x | 0.89x | 1.35x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LXRX Key Ratios
Lexicon Pharmaceuticals, Inc. (LXRX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -63.81% | -123.2% | - | 111.13% | -42.84% | -65.01% | -88.37% | -168.5% | -167.66% | -39.72% |
| Return on Invested Capital (ROIC) | - | - | - | 32.36% | -19.34% | -137.91% | -84.97% | -85.09% | -81.14% | -22.7% |
| Gross Margin | -96.76% | 97.9% | 96.06% | 99% | 91.96% | -18371.81% | -37681.29% | -4798.01% | 98.02% | 99.45% |
| Net Margin | -169.71% | -142.86% | -190.71% | 40.4% | -244.11% | -29448.99% | -73341.01% | -14710.88% | -644.78% | -101.08% |
| Debt / Equity | 0.64x | 4.72x | - | 2.11x | 0.08x | 0.02x | 0.47x | 1.14x | 0.74x | 0.58x |
| Interest Coverage | -19.02x | -18.42x | -4.80x | 7.00x | -3.03x | -108.59x | -36.14x | -13.00x | -11.86x | -5.87x |
| FCF Conversion | 1.24x | 1.44x | 1.23x | 0.87x | 2.44x | 0.99x | 0.87x | 0.91x | 0.89x | 1.35x |
| Revenue Growth | -35.9% | 8.4% | -30.03% | 409.54% | -92.55% | -98.76% | -53.36% | 766.19% | 2481.48% | 60.24% |
LXRX SEC Filings & Documents
Lexicon Pharmaceuticals, Inc. (LXRX) SEC filings — annual & quarterly reports (10-K, 10-Q)
LXRX Frequently Asked Questions
Lexicon Pharmaceuticals, Inc. (LXRX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Lexicon Pharmaceuticals, Inc. (LXRX) reported $49.8M in revenue for fiscal year 2025. This represents a 960% increase from $4.7M in 1999.
Lexicon Pharmaceuticals, Inc. (LXRX) grew revenue by 60.2% over the past year. This is strong growth.
Lexicon Pharmaceuticals, Inc. (LXRX) reported a net loss of $50.3M for fiscal year 2025.
Dividend & Returns
Lexicon Pharmaceuticals, Inc. (LXRX) has a return on equity (ROE) of -39.7%. Negative ROE indicates the company is unprofitable.
Lexicon Pharmaceuticals, Inc. (LXRX) had negative free cash flow of $67.9M in fiscal year 2025, likely due to heavy capital investments.
Explore More LXRX
Lexicon Pharmaceuticals, Inc. (LXRX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates